Full Press Release Details
PERRIGO COMPANY PLC ANNOUNCES PROPOSED PUBLIC OFFERING OF
SENIOR NOTES OF ITS FINANCE SUBSIDIARY, PERRIGO FINANCE UNLIMITED COMPANY
Dublin, Ireland (March 7, 2016) Perrigo Company plc ( Perrigo or the Company ) (NYSE: PRGO; TASE), a leading global
provider of Quality Affordable Healthcare Products , today announced that Perrigo Finance Unlimited Company, a finance subsidiary of Perrigo incorporated under the laws of Ireland (the Issuer ), commenced a registered
public offering of two series of senior notes (collectively, the Notes ). The Notes will be fully and unconditionally guaranteed on a senior unsecured basis by the Company. The exact terms and timing of the offering will depend upon
market conditions and other factors.
Perrigo intends to use the net proceeds of the offering to repay amounts borrowed under a senior unsecured 364-day
revolving credit agreement with the Issuer, as borrower, the Company, as guarantor, and a syndicate of financial institutions, as lenders, HSBC Bank USA, N.A., as administrative agent and Bank of America, N.A. and Morgan Stanley Senior Funding,
Inc., as syndication agents and a senior unsecured five-year revolving credit agreement with the Issuer, as borrower, the Company, as guarantor, and a syndicate of financial institutions, as lenders, JPMorgan Chase Bank, N.A., as administrative
agent and Barclays Bank plc, as syndication agent, with the balance used for general corporate purposes.
BofA Merrill Lynch, HSBC and Morgan Stanley are
the joint book-running managers in the offering.
The offering is being made pursuant to an effective shelf registration statement filed with the
Securities and Exchange Commission. The offering will be made only by means of a prospectus supplement relating to the offering and the accompanying base prospectus, copies of which may be obtained by contacting: HSBC Securities (USA) Inc. toll free
at (866) 811-8049; Merrill Lynch, Pierce, Fenner & Smith Incorporated toll free at (800) 294-1322; or Morgan Stanley & Co. LLC toll free at (866) 718-1649.
Perrigo Company plc is a top five global
over-the-counter ( OTC ) consumer goods and leading specialty pharmaceutical company, offering patients and customers high-quality products at affordable prices. From the Company s beginning in 1887 as a packager of home remedies, it
has grown to become the world s largest manufacturer of OTC healthcare products and supplier of infant formulas for the store brand market. The Company is also a leading provider of generic extended topical prescription products, and it
receives royalties from sales of the multiple sclerosis drug Tysabri . The Company provides Quality Affordable Healthcare Products across a wide variety of product categories and geographies, primarily in North America, Europe
and Australia, as well as in other markets, including Israel and China.
For more information:
Bradley Joseph, Vice President, Global Investor Relations and Communications, (269) 686-3373, E-mail: bradley.joseph@perrigo.com; and Arthur J. Shannon,
Vice President, Global Corporate Affairs and European Investor Relations, (269) 686-1709, E-mail: ajshannon@perrigo.com.
No Offer or Solicitation
This press release does not constitute an offer to sell, or an invitation to subscribe for, purchase or exchange, any securities, nor shall there be any sale,
issuance, exchange or transfer of the securities referred to in this announcement in any jurisdiction in contravention of applicable law.
Statement Regarding Forward-Looking Statements
This press release contains so-called forward-looking statements within the meaning of, and
subject to the safe harbor created by, Section 21E of the Securities Exchange Act of 1934, as amended. These statements relate to future events or the Company s future financial performance and involve known and unknown risks,
uncertainties and other factors that may cause the Company s, or its industry s, actual results, levels of activity, performance or achievements to be materially different from those expressed or implied by any forward-looking statements.
In particular, statements about the Company s expectations, beliefs, plans, objectives, assumptions, future events or future performance contained in this press release are forward-looking statements. In some cases, forward-looking statements
can be identified by terminology such as may, will, could, would, should, expect, plan, anticipate, intend, believe,
estimate, predict, potential or the negative of those terms or other comparable terminology. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and
projections. While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond
the Company s control. Risks and uncertainties include risks relating to the successful completion of the transactions contemplated herein. These and other important factors, including those discussed under Risk Factors in the
Company s Form 10-KT for the transition period from June 28, 2015 to December 31, 2015, in the subsequent filings with the SEC and in other investor communications of the Company from time to time, may cause actual results,
performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this document are made only as of the date hereof, and unless otherwise required by applicable
securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.